SCOLR Pharma, Inc. Reports Third Quarter 2009 Financi...( December 31 ...),Health

Date:11/6/2009

, December 31, 2008 2009 ---- ---- ASSETS Current Assets Cash and cash equivalents $1,946,908 $6,363,243 Accounts receivable 240,363 177,253 Interest and other receivables 6,282 1,157 Prepaid expenses and other assets 285,807 286,539 ----------- ----------- Total current assets 2,479,360 6,828,192 Property and Equipment - net of accumulated depreciation of $1,245,400 and $1,289,844, respectively 555,364 790,947 Intangible assets - net of accumulated amortization of $493,671 and $465,724, respectively 564,359 557,639 Restricted cash 473,711 473,711 ----------- ----------- $4,072,794 $8,650,489 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable $26,102 $238,701 Accrued liabilities 633,277 668,694 Current portion of term loan - 87,850 ----------- ----------- Total current liabilities 659,379 995,245 Deferred rent 271,790 310,010 Long-term portion of term loan - 23,269 ----------- -----
'/>"/>

SOURCE SCOLR Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
6. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
7. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
9. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
10. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound